News

  High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families. Two research groups within GenoMEL have looked at the risk of cancers other than melanoma in families with inherited mutations in the p16 or CDKN2A gene: a group in Stockholm Sweden and another in Leiden, the Netherlands. WeRead More

A predictive biomarker is a test which provides information for medical teams and patients about how likely a particular treatment is to benefit that patient and or the risk of side effects. Using predictive biomarkers is an important part of the aim to deliver “personalised medicine”.  That is, thatRead More

A summary by Professor Julia Newton-Bishop The second Melanoma Patient Conference took place in Birmingham this year on June 16th and 17th. It was expertly organised (as was the first ever conference) by Imogen Cheese. It was very well attended by people who have experienced melanoma themselves or inRead More

  The following information is provided for participants who consented to long-term follow up using information provided by Cancer Registries and the Office of National Statistics (ONS) as part of these studies:   The Melanoma Follow-Up and Case-Control Family Study. Ethics Committee number: MREC 01/3/057 A Genetic Epidemiological StudyRead More

Melanoma Focus (http://www.melanomafocus.com) has launched its Patient Decision Aid (PDA), whose aim is to inform people about melanoma and guide patients through the decisions they will need to take during their treatment. By helping people to understand their options, this new online tool should improve the effectiveness of conversations betweenRead More

Are you based in Leeds? We are a melanoma research group led by Professor JA Newton-Bishop and we aim to develop a blood test that measures immune function. We are doing this by comparing the genetic information in the immune cells of individuals who have illnesses that affect the immune system such as cancerRead More